This observation allows us to hypothesize that the link between TOP2A status and sensitivity to chemotherapy is not the only biomarker involved in pediatric osteosarcoma chemosensitivity, prognosis and outcome, which are closely linked. The gene discussed is TOP2A; the disease is osteosarcoma.